Trial · NCT02301039
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate | Soft Tissue Sarcoma | 7 | Participants | ||
| Objective Response Rate | Bone Sarcoma | 2 | Participants | ||
| Objective Response Rate | Expansion Cohort | 7 | Participants | ||
| Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient | Soft Tissue Sarcoma | 6 | Grade 3 or higher treatment related AEs | ||
| Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient | Bone Sarcoma | 9 | Grade 3 or higher treatment related AEs | ||
| Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient | Expansion Cohort | 10 | Grade 3 or higher treatment related AEs | ||
| The Progression-free Survival (PFS) | Soft Tissue Sarcoma | 18 | 95% Confidence Interval 8 to 22 | weeks | |
| The Progression-free Survival (PFS) | Bone Sarcoma | 8 | 95% Confidence Interval 7 to 9 | weeks | |
| The Progression-free Survival (PFS) | Expansion Cohort | 8 | 95% Confidence Interval 7 to 13 | weeks | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Soft Tissue Sarcoma | irCR | 1 | Participants | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Bone Sarcoma | irCR | 0 | Participants | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Expansion Cohort | irCR | 2 | Participants | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Soft Tissue Sarcoma | irPR | 2 | Participants | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Bone Sarcoma | irPR | 2 | Participants | |
| Response Rate by Immune-related Response Criteria (Ir-RC) | Expansion Cohort | irPR | 7 | Participants | |
| Overall Survival (OS) | Soft Tissue Sarcoma | 49 | 95% Confidence Interval 34 to 73 | weeks | |
| Overall Survival (OS) | Bone Sarcoma | 52 | 95% Confidence Interval 40 to 72 | weeks | |
| Overall Survival (OS) | Expansion Cohort | 57 | 95% Confidence Interval 33 to 86 | weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02301039/results